journal article·2025-05-06

A Self-Assembled Nanovaccine with BA.4/5 Receptor-Binding Domain and CpG Oligodeoxynucleotides Induces Broad-Spectrum Neutralization against SARS-CoV-2 Omicron Subvariants

Chendong Yang, Entao Li, Xiaoping Guo, Wenyu Xie, Yuanzhan Wang, Xuefei Huang, Sandra Chiu, Xuanjun Wu

ACS Nano· Volume 19· Issue 17
Publisher page

Abstract

Over the past 3 years, SARS-CoV-2 Omicron has been circulating globally with the emergence of multiple subvariants, including BA.5, BA.5.2, XBB, XBB.1, EG.5.1, HK.3, BA.2.86, JN.1, and KP.2. To combat these Omicron subvariants, several vaccines based on receptor-binding domain (RBD) dimers have been developed; however, RBD dimer vaccines require frequent updates to cope with the emergence of new variants. In contrast, the development of a safe, effective, and broad-spectrum vaccine against multiple Omicron subvariants, including the latest JN.1 and KP.2, would be a one-size-fits-all solution. Here, we designed BA.4/5 RBD-PC7A conjugate micelles by displaying the BA.4/5 RBD in PC7A micelles. Remarkably, the micelles elicited potent neutralizing antibodies (NAbs) in rabbits, effectively neutralizing BA.5.2, XBB.1.18, and HK.3 infections. Moreover, the micelles alone were able to induce NAbs in mice against the BA.5 variant. When a cytosine-phosphate-guanine (CpG) adjuvant was added and electrostatically adsorbed to the micelles, there was a significant increase in the antibody titers of IgG1, IgG2b, and IgG2c. This enhancement facilitated the broad neutralization of various strains, including BA.5.2, XBB.1.18, HK.3, JN.1, and KP.2. Furthermore, the micelles adsorbed with CpG protected golden hamsters from infection with the BA.5.2 strain. This study presents a potent and broadly neutralizing nanovaccine that includes the BA.4/5 RBD antigen and a CpG adjuvant. It demonstrates efficacy against multiple Omicron subvariants, including BA.5, BA.5.2, XBB.1.18, HK.3, JN.1, and KP.2, highlighting its potential for clinical translation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Glycoengineering Research Center, Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-based Medicine, Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs

Shandong University

Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine

University of Science and Technology of China

Departments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering

Michigan State University

Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases

Funding

National Key Research and Development Program of China · Taishan Scholar Project of Shandong Province · National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · Chinese Academy of Sciences

References (58)

Show source-provided references
1. 10.1038/s41586-020-2008-310.1038/s41586-020-2008-3 ↗
2. 10.1038/s41586-020-2798-310.1038/s41586-020-2798-3 ↗
3. FDA. COVID-19 Vaccines for 2024–2025. 2024. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2024-2025 (accessed 2024, 3 September).
4. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
5. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
6. 10.1056/NEJMoa210529010.1056/NEJMoa2105290 ↗
7. 10.1056/NEJMoa210154410.1056/NEJMoa2101544 ↗
8. 10.1126/science.abc193210.1126/science.abc1932 ↗
9. 10.1056/NEJMoa220226110.1056/NEJMoa2202261 ↗
10. 10.1056/NEJMoa210765910.1056/NEJMoa2107659 ↗
11. 10.1038/s41577-021-00662-410.1038/s41577-021-00662-4 ↗
12. 10.1038/s41467-022-29225-410.1038/s41467-022-29225-4 ↗
13. GISAID. Overview of Variants/Mutations. 2024. https://covariants.org/variants (accessed 2024, 9 October).
14. WHO. WHO COVID-19 dashboard. 2024. https://covid19.who.int/ (accessed 2024, 10 November).
15. 10.1038/s41586-020-2599-810.1038/s41586-020-2599-8 ↗
16. 10.1056/NEJMc221623310.1056/NEJMc2216233 ↗
17. 10.1038/s41541-024-01016-610.1038/s41541-024-01016-6 ↗
18. 10.1038/s41467-023-37417-910.1038/s41467-023-37417-9 ↗
19. 10.1038/s41565-020-0737-y10.1038/s41565-020-0737-y ↗
20. 10.1038/s41565-020-00790-310.1038/s41565-020-00790-3 ↗
21. 10.1002/advs.20220459810.1002/advs.202204598 ↗
22. 10.1002/adfm.20210505910.1002/adfm.202105059 ↗
23. 10.1002/adma.20210778110.1002/adma.202107781 ↗
24. 10.1038/s41423-022-00897-810.1038/s41423-022-00897-8 ↗
25. 10.1002/adhm.20230275510.1002/adhm.202302755 ↗
26. 10.1016/j.bioactmat.2024.02.02810.1016/j.bioactmat.2024.02.028 ↗
27. 10.1021/acsnano.4c0307510.1021/acsnano.4c03075 ↗
28. 10.1002/anie.20110088410.1002/anie.201100884 ↗
29. 10.1038/s41551-020-00675-910.1038/s41551-020-00675-9 ↗
30. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
31. 10.1016/j.jconrel.2019.02.03610.1016/j.jconrel.2019.02.036 ↗
32. 10.1016/j.jconrel.2020.11.05610.1016/j.jconrel.2020.11.056 ↗
33. 10.1021/acsnano.4c0092510.1021/acsnano.4c00925 ↗
34. 10.1002/mco2.46010.1002/mco2.460 ↗
35. 10.1309/NR8HN08GDPVEMU0810.1309/NR8HN08GDPVEMU08 ↗
36. 10.1073/pnas.210315411810.1073/pnas.2103154118 ↗
37. 10.1007/s11262-014-1049-910.1007/s11262-014-1049-9 ↗
38. 10.1038/s41467-021-21155-x10.1038/s41467-021-21155-x ↗
39. 10.1126/scitranslmed.abj530510.1126/scitranslmed.abj5305 ↗
40. 10.1038/nri132910.1038/nri1329 ↗
41. 10.1016/j.addr.2008.12.00810.1016/j.addr.2008.12.008 ↗
42. 10.1038/s41586-023-06809-810.1038/s41586-023-06809-8 ↗
43. 10.1038/s41586-020-2342-510.1038/s41586-020-2342-5 ↗
44. 10.3389/fmicb.2020.61889110.3389/fmicb.2020.618891 ↗
45. 10.3389/fimmu.2022.82166410.3389/fimmu.2022.821664 ↗
46. 10.1016/j.ijbiomac.2023.12681710.1016/j.ijbiomac.2023.126817 ↗
47. 10.1016/j.jconrel.2024.01.01710.1016/j.jconrel.2024.01.017 ↗
48. 10.1038/nmat505710.1038/nmat5057 ↗
49. 10.1126/science.abq083910.1126/science.abq0839 ↗
50. 10.1002/adma.20207037310.1002/adma.202070373 ↗
51. 10.1002/advs.20230103410.1002/advs.202301034 ↗
52. 10.1016/j.addr.2023.11489710.1016/j.addr.2023.114897 ↗
53. 10.1038/nature0847610.1038/nature08476 ↗
54. 10.1038/nri392110.1038/nri3921 ↗
55. 10.1002/anie.20210861010.1002/anie.202108610 ↗
56. 10.1021/jacs.8b0847310.1021/jacs.8b08473 ↗
57. 10.1126/sciadv.abj147610.1126/sciadv.abj1476 ↗
58. 10.1021/acsnano.0c0837910.1021/acsnano.0c08379 ↗